Omega - OMGA Earnings growth forecast for next year
Omega Therapeutics is a leader in epigenetics, managing gene expression without DNA breaks for cancer therapy. The company's annual EPS forecast confirms its status as a scientific vanguard in biotech, where 9.70 reflects the latest metric level. The issuer's operations are strictly regulated by FDA standards for biomaterial disposal, ensuring fundamental compliance with environmental norms.
omegatherapeutics.com (OMGA) - metric breakdowns and financial figures
- share price and consensus valuation forecast:
- issuer market value details:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Debt to Equity Omega Therapeutics|OMGA - Long-Term Liabilities to Equity|Short-Term Debt to Capital Omega Therapeutics, Inc.|OMGA - Company Cumulative Debt|Debt to Book Value Omega Therapeutics|OMGA - Company Long-Term Debts|Company Current Liabilities Omega Therapeutics|Quick Ratio omegatherapeutics.com
- net income and valuation ratios data:
OMGA - Net Financial Result|Projected Future Earnings Omega Therapeutics|OMGA - Price to Earnings Ratio|Future Price to Earnings Omega Therapeutics|OMGA - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics|OMGA - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Omega Therapeutics|OMGA - Net earnings per share for the last 12 months|Quarterly EPS earnings growth omegatherapeutics.com|OMGA - Net earnings per share change in current year|Earnings growth forecast for next year Omega Therapeutics
- sales and revenue indicators:
Fundamental company analysis:Omega
Investors utilize expected profit trends to assess the long-term viability of the business and its capitalization rates. This indicator measures the consolidated earnings per share (EPS) forecast for the coming year, reflecting market confidence in the success of Omega Therapeutics (OMGA) epigenetic developments, which allows for an assessment of the commercialization potential for chronic disease therapies through the current vector of next year's EPS projections.
Main competitors
TEM (Tempus AI, Inc) - Earnings growth forecast for next year|QGEN: Expected earnings per share trend next year|Earnings growth forecast for next year IONS|RGEN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Avidity Biosciences, Inc. RNA|Expected earnings per share trend next year CRSP|Sema4 - Earnings growth forecast for next year|RARE - Earnings growth forecast for next year|Beam Therapeutics Inc. (BEAM) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year SRPT (sarepta.com)|TWST (Twist Bioscience, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year 10x Genomics Inc TXG|Expected earnings per share growth for next year NTLA (Intellia)|Earnings growth forecast for next year Stoke Corp (STOK)|BioLife Solutions, Inc. - Expected earnings per share growth for next year|Projected earnings per share increase next year WVE (wavelifesciences.com)|Maze Therapeutics - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Sionna Therapeutics, Inc. SION|PRME: Earnings growth forecast for next year|Expected earnings per share growth for next year Taysha Corp|Net earnings per share growth forecast for next year uniQure N.V.|meiragtx.com (MGTX) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year REGENXBIO (RGNX)|SLDB - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Ocugen Corp OCGN|PACB - Expected earnings per share growth for next year|Benitec Biopharma Inc. - Earnings growth forecast for next year|Net earnings per one share growth forecast for next year designtx.com (DSGN)|RCKT: Earnings growth forecast for next year|4DMT (FDMT) - Earnings growth forecast for next year|LXEO (Lexeo Therapeutics Inc.) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year KRRO (Korro Bio, Inc)|Net earnings per share growth forecast for next year Editas Medicine, Inc. (EDIT)|silence-therapeutics.com - Projected earnings per share growth rate for next year|Earnings growth forecast for next year PRQR (ProQR Therapeutics)|Earnings growth forecast for next year Codexis Inc CDXS|SGMO - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Nautilus Biotechnology|Metagenomi, Inc. (MGX) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year Precision BioSciences Inc.|GBIO (Generation Bio Co) - Earnings growth forecast for next year|Expected net earnings per share growth next year Boundless Bio Inc. BOLD|Earnings growth forecast for next year XCUR|imunon.com (IMNN) - Net earnings per one share growth forecast for next year|Earnings growth forecast for next year PHIO (Phio Pharmaceuticals Corp.)|Earnings growth forecast for next year Mustang Bio Inc MBIO|RNAZ: Expected earnings per share growth for next year|Expected earnings per share trend next year BNGO (Bionano Genomics, Inc.)|APDN (Applied DNA) - Expected earnings per share growth for next year|BLUE: Projected earnings per share increase next year|IPA (ImmunoPrecise Antibodies Ltd) - Earnings growth forecast for next year|OMIC: Expected earnings per share trend next year|Earnings growth forecast for next year RGLS|SYRS - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Codex DNA TBIO|Expected earnings per share trend next year TCON|Unity Biotechnology - Earnings growth forecast for next year
